Skip to content

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020

STOCKHOLM, 25 May 2020 – Promore Pharma AB (publ) publishes its interim report for the first quarter 2020 at 13.00 CET on 26 May 2020.

 The next day, 27 May, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson, where an update for the quarter and the COVID-19 pandemic’s potential effects will be given. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet or telephone.

To join the web conference, please use the following link:

To join the conference call, please use one of the following numbers:

Sweden: +46 853 527 827

Denmark: +45 32 72 03 82

Finland: +358 942 72 1060

Norway: +47 21 93 37 51

Spain: +34 932 75 2004

United Kingdom: +44 330 221 0088

Germany: +49 721 9881 4161

Use the access code 615-361-109 to join the meeting.

The conference call will be recorded and made available on the company´s website after the call; After the annual general meeting that will take place on 26 May 2020, the address of the CEO will also be published on the company website.

For additional information, please contact

Jonas Ekblom, VD

Tel: [+46] 736 777 540



Jenni Björnulfson, CFO

Tel: [+46] 708 55 38 05


Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) is being evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market

Promore Pharma’s Certified Adviser is Redeye AB.

Phone: [+46] 8 121 576 90